UK industry calls for debate on access to new medicines
This article was originally published in Scrip
In the aftermath of NICE's proposal to reject four kidney cancer drugs for patients in England and Wales, the body that represents the UK pharmaceutical industry, theABPI, has called for professional organisations to publicly debate access to modern medicines.
You may also be interested in...
Cerimon Pharmaceuticals' once-daily topical-patch formulation of the NSAID diclofenac gave significantly better average pain relief than placebo in ankle-sprain patients who carried out their daily activities in a Phase II trial, at the third day in the study.
Following a second resubmission, the Scottish Medicines Consortiumhas accepted Lilly's Alimta (pemetrexed) for restricted use within the Scottish NHS as a monotherapy for the second-line treatment of locally advanced or metastatic non-small cell lung cancer.